Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Accumulated Expenses (2020 - 2025)

Maxcyte (MXCT) has disclosed Accumulated Expenses for 6 consecutive years, with $8.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 1.34% to $8.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.3 million, a 1.34% increase, with the full-year FY2024 number at $8.3 million, down 26.33% from a year prior.
  • Accumulated Expenses was $8.3 million for Q3 2025 at Maxcyte, up from $6.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $11.3 million in Q4 2023 to a low of $3.9 million in Q1 2022.
  • A 5-year average of $7.1 million and a median of $7.0 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 78.59% in 2023, then decreased 26.33% in 2024.
  • Maxcyte's Accumulated Expenses stood at $6.5 million in 2021, then increased by 26.7% to $8.3 million in 2022, then surged by 36.35% to $11.3 million in 2023, then fell by 26.33% to $8.3 million in 2024, then increased by 0.05% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Accumulated Expenses are $8.3 million (Q3 2025), $6.4 million (Q2 2025), and $5.0 million (Q1 2025).